All In MedTech

FDA Clearance Tracker · P170035-S003

BAUSCH + LOMB Ultra (samfilcon A) Multifocal for Astigmatism Contact Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 8, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 8, 2019

Approved

Time to decision

93 days

Received Feb 4, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170035-S003
Device name
BAUSCH + LOMB Ultra (samfilcon A) Multifocal for Astigmatism Contact Lens
Applicant location
Rochester, NY
Received
Feb 4, 2019
Decided
May 8, 2019
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P170035

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

Approval for Multifocal for Astigmatism.

Source documents

Other decisions for Bausch and Lomb, Inc.,

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.